By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioLogics, Inc. (VA) 

9020 Euclid Avenue
Suite H
Manassas  Virginia  20110  U.S.A.
Phone: 703-367-9020 Fax: 703-367-9204


SEARCH JOBS


Industry
Suppliers






Company News
BioLogics Release: NERLYNX (Neratinib) Tablets Approved For HER2+ Breast Cancer In The Extended Adjuvant Setting 7/21/2017 7:54:51 AM
BioLogics’ Patient Access Services Team Procures More Than $44 Million In Co-Pay Assistance For Cancer Patients In 2016 5/24/2017 9:24:50 AM
IMFINZI (Durvalumab) Approved For Previously Treated Patients With Advanced Bladder Cancer, Available Immediately At BioLogics 5/22/2017 7:35:05 AM
ALUNBRIG (Brigatinib) Approved For The Treatment Of ALK+ Metastatic Non-Small Cell Lung Cancer, Available For Order At BioLogics 5/11/2017 8:33:29 AM
RYDAPT (Midostaurin) Approved For The Treatment Of FLT3-Mutated Acute Myeloid Leukemia, Available For Order At BioLogics 5/3/2017 8:21:53 AM
BioLogics Selected By Tesaro (TSRO) As A Specialty Pharmacy Provider For ZEJULATM (Niraparib), Approved For The Treatment Of Recurrent Ovarian Cancer 4/24/2017 12:18:04 PM
BAVENCIO (Avelumab) Approved For The Treatment Of Metastatic Merkel Cell Carcinoma, Available For Order At BioLogics 3/29/2017 7:26:16 AM
BioLogics Release: KISQALI (Ribociclib) Approved For The Treatment Of HR+/HER2- Advanced Breast Cancer 3/17/2017 8:20:21 AM
BioLogics Release: XERMELO (Telotristat Ethyl) Approved For The Treatment Of Carcinoid Syndrome 3/1/2017 8:20:06 AM
CABOMETYX (Cabozantinib) Tablets Approved For Advanced Renal Cell Carcinoma, Available At BioLogics 10/5/2016 8:31:33 AM
//-->